Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies

Abstract A candidate multigenic SARS-CoV-2 vaccine based on an MVA vector expressing both viral N and S proteins (MVA-S + N) was immunogenic, and induced T-cell responses and binding antibodies to both antigens but in the absence of detectable neutralizing antibodies. Intranasal immunization with th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chaojie Zhong, Hongjie Xia, Awadalkareem Adam, Binbin Wang, Renee L. Hajnik, Yuejin Liang, Grace H. Rafael, Jing Zou, Xiaofang Wang, Jiaren Sun, Lynn Soong, Alan D. T. Barrett, Scott C. Weaver, Pei-Yong Shi, Tian Wang, Haitao Hu
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Acceso en línea:https://doaj.org/article/378daaf3c6264d6f95e72af6146211c7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract A candidate multigenic SARS-CoV-2 vaccine based on an MVA vector expressing both viral N and S proteins (MVA-S + N) was immunogenic, and induced T-cell responses and binding antibodies to both antigens but in the absence of detectable neutralizing antibodies. Intranasal immunization with the vaccine diminished viral loads and lung inflammation in mice after SARS-CoV-2 challenge, which correlated with the T-cell response induced by the vaccine in the lung, indicating that T-cell immunity is also likely critical for protection against SARS-CoV-2 infection in addition to neutralizing antibodies.